Turn Biotechnologies and HanAll Biopharma Sign Global Deal for Eye and Ear Therapies

MOUNTAIN VIEW, Calif., May 28, 2024 -- Turn Biotechnologies, a developer of innovative mRNA therapeutics, has entered into a worldwide licensing agreement with HanAll Biopharma to advance treatments for age-related eye and ear diseases. This strategic alliance is projected to surpass $300 million in value for the initial product, broadening an already existing relationship between the companies. HanAll first invested in Turn Bio in 2022, recognizing the potential of its pioneering technologies.

Cutting-Edge Collaboration in Anti-Aging Treatments

The products emanating from this partnership will leverage Turn Bio's proprietary Epigenetic Reprogramming of Age (ERATM) technology and its eTurna™ delivery system. These technologies are designed to rejuvenate gene expression and address the cellular deterioration that accompanies aging, thereby treating and potentially curing chronic conditions.

Turn Bio’s CEO, Anja Krammer, emphasized the significance of this collaboration: "This partnership marks a pivotal development for Turn Bio. With HanAll's expertise, we are fast-tracking the creation of groundbreaking therapies for eye and ear conditions that could significantly impact patients globally. This is merely the starting point for what we can achieve together."

HanAll Biopharma CEO, Sean Jeong, M.D., MBA, highlighted the alignment of Turn Bio's technological advancements with HanAll's mission to explore innovative medical solutions. "Turn Bio's approach to epigenetic reprogramming fits seamlessly with our goal to develop novel therapies. Together, we are set to address critical unmet medical needs, particularly in age-related diseases."

Pioneering Regenerative Medicine

This collaboration significantly extends Turn Bio's research, which has been predominantly focused on dermatology and immunology, to also include ophthalmology and otology. This expanded focus could lead to treatments for a broader array of age-related diseases.

"The true power of ERA™ technology lies in its ability to rejuvenate cells in any organ," stated Vittorio Sebastiano, co-founder of Turn Bio and head of research. "This agreement allows us to expedite our efforts to reverse aging damage and enhance the quality of life for older adults."

About Turn Biotechnologies

Turn Biotechnologies is a pre-clinical company committed to cellular-level tissue repair through its mRNA-based ERA™ technology. This technology aims to restore gene expression affected by aging, thereby rejuvenating cells’ ability to heal and regenerate tissue. The company's eTurna™ platform delivers precise therapeutic agents to specific tissues and organs. Turn Bio is also exploring treatments in dermatology, immunology, ophthalmology, osteoarthritis, and muscular conditions.

About HanAll Biopharma

HanAll Biopharma is a global biopharmaceutical entity with operations in Korea, the USA, Japan, and Indonesia. With a legacy of over 50 years, HanAll focuses on treating severe unmet medical needs through innovative pharmaceuticals. The company is expanding its research into immunology, oncology, neurology, and ophthalmology. HanAll's leading projects include HL161 (batoclimab) for autoimmune diseases and HL036 (tanfanercept) for dry eye disease, both in advanced clinical trials. Other promising assets like HL161ANS and HL192 are also in early-stage clinical evaluations.

This partnership between Turn Biotechnologies and HanAll Biopharma represents a significant step forward in the development of regenerative treatments aimed at improving the lives of patients suffering from age-related conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!